Persistent cerebrovascular effects of MDMA and acute responses to the drug

European Journal of Neuroscience

Volumn 24, Issue 2, 2006, Pages 509-519

  Ferrington, Linda ^a   Kirilly, Eszter ^b   McBean, Douglas E ^c   Olverman, Henry J ^a   Bagdy, György ^b,d   Kelly, Paul A T ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^c QUEEN MARGARET UNIVERSITY   (United Kingdom)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Dark agouti rat; Flow metabolism relationship; Local cerebral blood flow; Local cerebral glucose utilization; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CARBON 14; DEOXYGLUCOSE; GLUCOSE; IODOPHENAZONE C 14; PAROXETINE; SEROTONIN TRANSPORTER; SODIUM CHLORIDE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; AUTOREGULATION; BRAIN BLOOD FLOW; CARDIOVASCULAR AUTOREGULATION; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; GLUCOSE BRAIN LEVEL; GLUCOSE UTILIZATION; HYPERTENSION; IMAGING; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SEROTONINERGIC NERVE CELL; STATISTICAL SIGNIFICANCE;

ACUTE DISEASE; ANIMALS; ANTIPYRINE; AUTONOMIC PATHWAYS; CARBON RADIOISOTOPES; CEREBRAL ARTERIES; CEREBRAL CORTEX; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; DEOXYGLUCOSE; GLUCOSE; HOMEOSTASIS; HYPEREMIA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PRESYNAPTIC TERMINALS; RADIOLIGAND ASSAY; RATS; SEROTONIN; SEROTONIN AGENTS; SYNAPTIC TRANSMISSION; TIME; VASOCONSTRICTION;

EID: 33746210818     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2006.04923.x     Document Type: Article

References (91)

1. Agaba, E.A., Lynch, R.M., Baskaran, A. & Jackson, T. (2002) Massive intracerebral hematoma and extradural hematoma in amphetamine abuse. Am. J. Emerg. Med., 20, 55-57.
2. Auer, J., Berent, R., Weber, T., Lassnig, E. & Eber, B. (2002) Subarachnoid haemorrhage with 'ecstasy' abuse in a young adult. Neurol. Sci., 23, 199-201.
3. Badon, L.A., Hicks, A., Lord, K., Ogden, B.A., Meleg-Smith, S. & Varner, K.J. (2002) Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of ecstasy. J. Pharm. Exp. Ther., 302, 898-907.
4. Balogh, B., Molnar, E., Jakus, R., Quate, L., Olverman, H.J., Kelly, P.A.T., Kantor, S. & Bagdy, G. (2004) Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naïve rats and rats previously exposed to MDMA. Psychopharmacology, 173, 296-309.
5. 3H]paroxetine- labelled serotonin uptake sites. J. Pharmacol. Exp. Ther., 242, 911-916.
6. Battaglia, G., Yeh, S.Y. & De Souza, E.B. (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav., 29, 269-274.
7. Berntman, L., Carlsson, C., Hagerdal, M. & Siesjö, B.K. (1978) Circulatory and metabolic effects in the brain induced by amphetamine sulphate. Acta Physiol. Scand., 102, 310-323.
8. Bill, A. & Linder, J. (1976) Sympathetic control of cerebral blood flow in acute arterial hypertension. Acta Physiol. Scand., 96, 114-121.
9. Bonvento, G., Lacombe, P., MacKenzie, E.T., Fage, D., Benavides, J., Rouquier, L. & Scatton, B. (1991) Evidence for differing origins of the serotonergic innervation of major cerebral arteries and small pial vessels in the rat. J. Neurochem., 56, 681-689.
10. Carlsson, C., Hagerdal, M. & Siesjö, B.K. (1975) Influence of amphetamine sulphate on cerebral blood flow and metabolism. Acta Physiol. Scand., 94, 128-129.
11. Colado, M.I., Murray, T.K. & Green, A.R. (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol., 108, 583-589.
12. Colado, M.I., O'Shea, E. & green, A.R. (2004) Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology, 173, 249-263.
13. Colado, M.I., Williams, J.L. & Green, A.R. (1995) The hyperthermic and neurotoxic effects of 'ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol., 115, 1281-1289.
14. Commins, D.L., Vosner, G., Virus, R.M., Woolverton, W.L., Schuster, C.R. & Seiden, C.S. (1987) Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther., 241, 338-345.
15. Darvesh, A.S. & Gudelsky, G.A. (2005) Evidence for a role of energy dysregulation in the MDMA-induced depletion of brain 5-HT. Brain Res., 1056, 168-175.
16. Des Rosiers, M.H., Kennedy, C., Patlak, C.S., Pettigrew, K.D., Sokoloff, L. & Reivich, M. (1974) Relationships between local cerebral blood flow and glucose utilization in the rat. Neurology, 24, 389-396.
17. Edvinsson, L., McCulloch, J. & Sharkey, J. (1985) Vasomotor responses of cerebral arterioles in situ to putative dopamine receptor agonists. Br. J. Pharmacol., 85, 403-410.
18. Edvinsson, L., Owman, C. & Siesjö, B. (1976) Physiological role of cerebrovascular sympathetic nerves in the autoregulation of cerebral blood flow. Brain Res., 117, 519-523.
19. Felten, D.L. & Crutcher, K.A. (1979) Neuronal-vascular relationships in the raphe nuclei, locus coeruleus and substantia nigra in primates. Am. J. Anat., 155, 467-482.
20. Ferron, A., Descarries, L. & Reader, T.A. (1982) Altered neuronal responsiveness to biogenic amines in rat cerebral cortex after serotonin denervation or depletion. Br. Res., 231, 93-108.
21. Florence, G., Bonnier, R., Plagnes, D., Pierard, C., Satabin, P., Peres, M. & Lagarde, D. (2000) Effect of modafinil on cerebral blood flow of anaesthetised rats. Comparison with amphetamine. Exp. Brain Res., 135, 552-556.
22. Forster, C., Drew, G.M., Hilditch, A. & Whalley, E.T. (1983) Dopamine receptors in human basilar arteries. Eur. J. Pharmacol., 87, 227-235.
23. Frederick, D.L. & Paule, M.G. (1997) Effect of MDMA on complex brain function in laboratory animals. Neurosci. Biobehav. Rev., 21, 67-78.
24. Fu, L.H. W. & Toda, N. (1983). Analysis of the contractile response to serotonin and tryptamine of isolated dog cerebral, femoral and mesenteric arteries. Jpn. J. Pharmacol., 33, 473-480.
25. Gledhill, J.A., Moore, D.F., Bell, D. & Henry, J.A. (1993) Subarachnoid haemorrhage associated with MDMA abuse. J. Neurol. Neurosurg. Psych., 56, 1036-1037.
26. Graham, D.I., Grome, J.J., Kelly, P.A.T., MacKenzie, E.T., McCulloch, J., Reis, D.J. & Talman, W.T. (1982) Cerebral circulatory effects of fulminating neurogenic hypertension. In Heistad, D.D. & Marcus, M.L., (Eds), Cerebral Blood Flow: Effects of Nerves and Neurotransmitters. Elsevier, New York, pp. 493-502.
27. Green, A.R., Cross, A.J. & Goodwin, G.M. (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy'). Psychopharmacol., 119, 247-260.
28. Green, A.R., Mechan, A.O., Elliot, J.M., O'Shea, E. & Colado, M.I. (2003) The pharmacology and clinical pharmacology of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol. Rev., 55, 463-508.
29. Grome, J.J. & Harper, A.M. (1983) The effects of serotonin on local cerebral blood flow. J. Cereb. Blood Flow Metab., 3, 71-77.
30. Hanyu, S., Ikeguchi, K., Imai, H., Imai, N. & Yoshida, M. (1995) Cerebral infarction associated with 3,4-methylenedioxymethamphetamine ('ecstasy') abuse. Eur. Neurol., 35, 173.
31. Harkin, A., Connor, T.J., Mulrooney, J., Kelly, J.P. & Leonard, B.E. (2001) Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in. Rats, 68, 1367-1382.
32. Harper, A.M. & MacKenzie, E.T. (1977)Cerebral circulatory and metabolic effects of 5-hydroxytryptamine in anaesthetized baboons. J. Physiol., 271, 735-746.
33. Harries, D.P. & De Silva, R. (1992) 'Ecstasy' and intracerebral haemorrhage. S. Med. J., 37, 150-152.
34. Head, R.J., Hjelle, J.T., Jarrott, B., Berkowitz, B., Cardinale, G. & Spector, S. (1980) Isolated brain microvessels: preparation, morphology, histamine and catecholamine contents. Blood Vessels, 17, 173-186.
35. Hegadoren, K.M., Baker, G.B. & Bourin, M. (1999). 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci. Biobehav. Rev., 23, 539-553.
36. Henry, J.A., Jeffreys, K.J. & Dawling, S. (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("Ecstasy"). Lancet, 340, 384-387.
37. Hewitt, K.E. & Green, A.R. (1994) Chlomethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (ecstasy). Neuropharmacol., 33, 1589-1595.
38. Kaku, D.A. & Lowenstein, D.H. (1990) Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann. Intern. Med., 113, 821-827.
39. 1 agonists. Neuroscience, 25, 907-915.
40. Kelly, P.A.T., Ritchie, I.M., McBean, D.E., Sharkey, J. & Olverman, H.J. (1995) Enhanced cerebrovascular responsiveness to hypercapnia following depletion of central serotonergic terminals. J. Cereb. Blood Flow Metab., 15, 706-713.
41. Kirilly, E., Benko, A., Ferrington, L., Kelly, P.A.T. & Bagdy, G. (2006) Acute and long-term effects of a single dose of MDMA on aggression in Dark Agouti rats. Int. J. Neuropsychopharm., 9, 63-76.
42. Kirilly, E., Toth, Z.E., Gerber, G., Palkovits, M. & Bagdy, G. (2005) 3,4-methylendioxymethamphetamine modulates serotonin transporter mRNA expression in the rat brainstem. Soc. Neurosci. Abstr., 111.12 2005.
43. Koch, S. & Galloway, M.P. (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural. Trans., 104, 135-146.
44. Leonardi, E.T.K. & Azmitia, E.C. (1994) MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharm., 10, 231-238.
45. Lew, R., Sabol, K.E., Chou, C., Vosmer, G.L., Richards, J. & Seiden, L.S. (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: radioligand binding and autoradiography studies. J. Pharmacol. Exp. Ther., 276, 855-865.
46. Li, A.A., Marek, G.J., Vocmer, G. & Seiden, L.S. (1989). Long-term central 5-HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of schedule-controlled behaviour of rats. Pharmacol. Biochem. Behav., 33, 641-648.
47. Lou, H.C., Edvinsson, L. & MacKenzie, E.T. (1987). The concept of coupling flow to brain function: revision required? Ann. Neurol., 22, 289-297.
48. MacKenzie, E.T., McGeorge, A.P., Graham, D.I., Fitch, W., Edvinsson, L. & Harper, A.M. (1979) Effects of increasing arterial pressure on cerebral blood flow in the baboon: influence of the sympathetic nervous system. Pflügers Arch., 378, 189-195.
49. MacKenzie, E.T., Strandgaard, S., Graham, D.I., Jones, J.V., Harper, A.M. & Farrar, J.K. (1976) Effect of acutely induced hypertension in cats on pial arteriolar caliber, local cerebral blood flow and the blood-brain barrier. Circ. Res., 39, 33-41.
50. 123i]-2βcarbomethoxy- 3β-(4-iodophenyl) tropane and single photon emission computed tomography. Biol. Psych., 44, 1090-1098.
51. McBean, D.E., Sharkey, J., Ritchie, I.M. & Kelly, P.A.T. (1991). Cerebrovascular and functional consequences of 5-HT1A receptor activation. Brain Res., 555, 159-163.
52. McCann, D.U., Szabo, Z., Scheffel, U., Dannals, R.F. & Ricaurte, G.A. (1998) Positron emission tomographic evidence of toxic effect of MDMA (ecstasy) on brain serotonin neurons in human beings. Lancet, 352, 1433-1437.
53. McEvoy, A.E., Kitchen, N.D. & Thomas, D.G.T. (2000) Intracerebral haemorrhage in young adults: the emerging importance of drug misuse. Br. Med. J., 320, 1322-1324.
54. McKenna, D.J. & Peroutka, S.J. (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). J. Neurochem., 54, 14-22.
55. Miranda, J. & O'Neill, D. (2002) Stroke associated with amphetamine use. Ir. Med. J., 95, 281-282.
56. Molliver, M.E., Berger, W.V., Mamounas, L.A., Molliver, D.C., O'Hearn, E. & Wilson, M. (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann. N.Y. Acad. Sci., 600, 640-664.
57. Nash, J.F. & Yamamoto, B.K. (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res., 581, 237-243.
58. Nichols, D.E. & Oberlender, R. (1990) Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Ann. N.Y. Acad. Sci., 600, 612-623.
59. Nixdorf, W.L., Burrows, K.B., Gudelsky, G.A. & Yamamoto, B.K. (2001) Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J. Neurochem., 77, 647-654.
60. O'Hearn, E., Battaglia, G., De Souza, E.B., Kuhar, M.J. & Molliver, M.E. (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci., 8, 2788-2803.
61. O'Shea, E., Granados, R., Esteban, B., Colado, M.I. & Green, A.R. (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacol., 37, 919-926.
62. Paulson, O.B., Strandgaard, S. & Edvinsson, L. (1990) Cerebral autoregulation. Cerebrovasc. Brain Metab. Rev., 2, 161-192.
63. Perez, J.A., Arsura, E.L. & Strategos, S. (1999) Methamphetamine- related stroke: four cases. J. Emerg. Med., 17, 469-471.
64. Petitti, D.B., Sidney, S., Queensberry, C. & Bernstein, A. (1998) Stroke and cocaine or amphetamine use. Epidemiology, 9, 596-600.
65. Quate, L., McBean, D.E., Ritchie, I.M., Olverman, H.J. & Kelly, P.A.T. (2004) Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the dark agouti rat. Psychopharmacology, 173, 287-295.
66. Reneman, L., Lavalaye, J., Schmand, B., de Wolff, F.A., van den Brink, W., den Heeten, G.J. & Booij, J. (2001) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4- methylenedioxymethamphetamine (MDMA or 'ecstasy'): preliminary findings. Arch. Gen. Psychol., 58, 901-906.
67. Rosa-Neto, P., Olesen, A.K., Gjedde, A., Watanabe, H. & Cumming, P. (2004) MDMA-evoked changes in cerebral blood flow in living porcine brain; correlation with hyperthermia. Synapse, 53, 214-221.
68. Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I. & Partilla, J.S. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39, 32-41.
69. Rudnick, G. & Wall, S.C. (1992) The molecular mechanism of 'ecstasy' [3,4-methylenedioxymethamphetamine (MDMA) ]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl Acad. Sci. USA, 89, 1817-1821.
70. Russo, K.E., Hall, W., Chi, O.Z., Sinha, A.K. & Weiss, H.R. (1991) Effect of amphetamine on cerebral blood flow and capillary perfusion. Brain Res., 542, 43-48.
71. Sabol, K.E., Lew, R., Richards, J.B., Vosmer, G.L. & Seiden, L.S. (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: synaptosomal uptake and tissue concentrations. J. Pharmacol. Exp. Ther., 276, 846-854.
72. Sadoshima, S., Fujishima, M., Yoshida, F., Ibayashi, S., Shiokawa, O. & Omae, T. (1985) Cerebral autoregulation in young spontaneously hypertensive rats. Effect of sympathetic denervation. Hypertension, 7, 392-397.
73. 14C]antipyrine. Am. J. Physiol., 234, H59-H66.
74. Scanzello, C.R., Hatzidimitriou, G., Martello, A.L., Katz, J.L. & Ricaurte, G.A. (1993) Serotonergic recovery after (±)-3,4- (methylenedioxy) methamphetamine injury: observations in rats. J. Pharmacol. Exp. Ther., 264, 1484-1491.
75. Scatton, B., Deverger, D., L'Heuruex, R., Serrano, A., Fage, D., Nowicki, J-P. & MacKenzie, E.T. (1985). Neurochemical studies on the existence, origin and characteristics of the serotonergic innervation of small pial vessels. Brain Res., 345, 219-229.
76. Schmidt, C.J. (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther., 240, 1-7.
77. Schmidt, C.J., Wu, L. & Lovenberg, W. (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur. J. Pharmacol., 124, 175-178.
78. Sharkey, J., McBean, D.E. & Kelly, P.A.T. (1991) Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine. ('Ecstasy') Psychopharmacol., 105, 113-118.
79. 14C]deoxyglucose method for the measurement of local cerebral glucose utilisation: theory, procedure and normal values in the conscious and anesthetized albino rat. J. Neurochem., 28, 897-916.
80. Steinbusch, H.M.W. (1981) Distribution of serotonin-immunoreactivity in the central nervous system of the rat, cell bodies and terminals. Neuroscience, 6, 557-618.
81. Stone, D.M., Merchant, K.M., Hanson, G.R. & Gibb, J.W. (1987) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology, 26, 1677-1683.
82. Stone, D.M., Stahl, D.C., Hanson, G.R. & Gibb, J.W. (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4- methylenedioxyamphetamine (MDA) on monoaminergic systems in rat brain. Eur. J. Pharmacol., 128, 41-48.
83. Toda, N., Hayashi, S., Fu, W.L.H & Nagasaka, Y. (1976). Serotonin antagonism in isolated canine cerebral arteries. Jpn. J. Pharmacol., 26, 57-63.
84. Trulson, M.E., Eubanks, E.E. & Jacobs, B.L. (1976) Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine. J. Pharmacol., Exp. Ther., 198, 23-32.
85. Tuor, U.I. & McCulloch, J. (1986) Regional cerebral perfusion during hypertension depends upon the hypertensive agent. Neurosci. Lett., 63, 253-258.
86. Vollenweider, F.X., Gamma, A., Liechti, M. & Huber, T. (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstacy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology, 19, 241-251.
87. Wang, X.Y., Baumann, M.H., Xu, H., Morales, M. & Rothman, R.B. (2005) (+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J. Pharmacol. Expt. Ther., 314, 1002-1012.
88. White, S.R., Obradovic, T., Imel, K.M. & Wheaton, M.J. (1996) The effects of methylenedioxymethamphetamine (MDMA, 'ecstasy') on monoaminergic neurotransmission in the central nervous system. Prog. Neurobiol., 49, 455-479.
89. Wichems, C.H., Hollingsworth, C.K. & Bennet, B.A. (1995) Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphé neurons: further evidence for calcium-independent mechanisms of release. Brain Res., 695, 10-18.
90. Wilkerson, G. & London, E.D. (1989) Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat. Neuropharmacology, 28, 1129-1138.
91. Xie, T., Tong, L., McLane, M.W., Hatzidimitriou, G., Yuan, J., McCann, U. & Ricaurte, G. (2006) Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology, in press.